As part of a research collaboration, the firms will develop AAV vectors for use in low-dose systemic gene therapies and in vivo CAR T-cell therapies.

At a public hearing hosted by the FDA, stakeholders said the program needs clearer eligibility criteria and insight into how ...

The recommendation is based on data showing that women lived an average of 16.9 months on the ADC compared to 13 months on chemo.

At ASCO, researchers reported that more patients who switched to camizestrant at molecular progression had total ctDNA ...

At ASCO, the company reported 9 partial responses during the dose-escalation phase of the study in neuroendocrine tumors.

Researchers are refining autologous tumor-infiltrating lymphocyte treatment while testing CAR T-cell therapies in new tumor ...

The firm has submitted data showing arcotatug tavatecan improves progression-free survival in previously treated patients with CLDN18.2-expressing tumors.

Inceptive Nucleics will receive $30 million upfront from Alnylam Pharmaceuticals in the form of cash and the purchase of equity.